Asian Journal of Pharmaceutical Research and Health Care, published by Wolters Kluwer Medknow Publications, serves as a vital platform for disseminating cutting-edge research in the fields of pharmacology, toxicology, and healthcare. With an ISSN of 2250-1444 and an E-ISSN of 2250-1460, this journal aims to provide valuable insights and advancements in pharmaceutical sciences, targeting researchers, practitioners, and students dedicated to improving health outcomes. Although its coverage in Scopus was discontinued in 2016, the journal maintains importance within the academic community by fostering discourse and sharing knowledge on emerging topics. Despite its challenges reflected in the low Scopus ranking within its category, the Asian Journal of Pharmaceutical Research and Health Care remains committed to enhancing access to critical research and publishing high-quality work that bridges the gap between theory and practice in health care. Researchers and professionals engaged in the pharmaceutical field are encouraged to contribute and leverage this journal as a means to advance their work and elevate healthcare standards in Asia and beyond.

Journal of Research in Pharmacy, published by Marmara University, serves as a pivotal platform for the dissemination of innovative research in the field of pharmacology and pharmaceutical sciences. With an ISSN of 2630-6344 and an E-ISSN of the same, this journal is dedicated to publishing high-quality research spanning various aspects of pharmacology, toxicology, and pharmaceutics. The journal, categorized in Q3 for both pharmacology (medical) and miscellaneous pharmacology, toxicology, and pharmaceutics in 2023, showcases the ongoing evolution of these disciplines amid growing scientific inquiry. As of now, it ranks #56/80 in general pharmacology, toxicology and pharmaceutics, spotlighting its relevance within the academic community. Although it operates under a traditional access model, the journal is committed to providing researchers, professionals, and students with a comprehensive understanding of contemporary challenges and innovations in pharmacy research. Established in 2019, it continues to foster academic dialogue and contribute significantly to the advancement of pharmacological sciences until at least 2024. For all interested in cutting-edge pharmaceutical research, this journal presents an invaluable resource from its base in Istanbul, Turkey.

JOURNAL OF CONTROLLED RELEASE is a premier academic journal published by Elsevier that is dedicated to advancing the field of pharmaceutical science with a focus on drug delivery systems. Established in 1984, the journal has consistently served as a vital platform for disseminating high-quality research and innovative ideas in the area of controlled release technologies. With an impressive impact factor and ranking in the Q1 category of Pharmaceutical Science, it ranks #3 out of 183 in Scopus for its field, reflecting its influence and significance within the academic community, as noted by its percentile of 98th. The journal encompasses a wide range of topics, including polymer science, pharmacokinetics, and bioengineering, ensuring it remains at the forefront of pharmaceutical advancements. While currently not offering open access options, the journal serves a diverse audience of researchers, professionals, and students who are eager to push the boundaries of knowledge in drug delivery and therapeutics. For those looking to make impactful contributions in this dynamic field, JOURNAL OF CONTROLLED RELEASE is an essential resource for both foundational studies and cutting-edge research findings.

The Future Journal of Pharmaceutical Sciences, published by Springer, stands as a vital resource in the realm of pharmaceutical research and innovation. Recognized for its open access initiative since 2015, this journal promotes extensive dissemination of cutting-edge discoveries, fostering collaboration among researchers, industry professionals, and students alike. With an ISSN of 2314-7245 and an E-ISSN of 2314-7253, it aims to bridge the gap between laboratory research and practical applications in the pharmaceutical sciences. Although specific metrics like HIndex and Scopus ranks are currently unavailable, the journal's commitment to high-quality, peer-reviewed content positions it as a promising platform for advancing pharmaceutical science. By engaging with this journal, contributors and readers can participate in the vibrant discourse shaping the future of drug development, therapeutic strategies, and healthcare solutions.

ACTA PHARMACEUTICA is a distinguished open-access journal published by SCIENDO, dedicated to advancing knowledge in the fields of medicine and pharmaceutical sciences. Established in 1992, the journal has made significant contributions to the scholarly community, providing a platform for innovative research and discussion. With a strong presence in both Q2 and Q3 quartiles across various categories including Pharmaceutical Science and Pharmacology, ACTA PHARMACEUTICA ranks favorably, positioning its contributions in the upper tiers of the field. The journal's commitment to open access since 2007 ensures that both practitioners and scholars have immediate access to cutting-edge developments, thereby fostering collaboration and knowledge sharing. With its scope spanning a broad spectrum of pharmaceutical and biomedical research, ACTA PHARMACEUTICA is an essential resource for researchers, professionals, and students keen to stay abreast of the latest advancements and trends in these vital areas of study.

The JOURNAL OF PHARMACEUTICAL SCIENCES, published by ELSEVIER SCIENCE INC, stands as a cornerstone in the field of pharmaceutical sciences, offering a platform for innovative research and advancements since its inception in 1961. With an impressive Scopus Rank of #36 out of 183 in the Pharmaceutical Science category, this journal is recognized for its commitment to disseminating high-quality, peer-reviewed studies that significantly contribute to the realms of pharmacology, toxicology, and pharmaceutics. Holding a 2023 Q2 category quartile, it attracts a diverse readership encompassing researchers, industry professionals, and students eager to advance their understanding and expertise. While the journal is not open access, it ensures valuable insights in every issue, making it an essential resource for those dedicated to the evolving landscape of pharmaceutical research. With an impact factor that reflects its relevance and influence, the JOURNAL OF PHARMACEUTICAL SCIENCES continues to shape the discourse in its domain, fostering innovation and collaboration among scholars worldwide.

Journal of Pharmacy and Pharmacology, published by Oxford University Press, is a prestigious academic journal dedicated to the advancement of knowledge in the fields of pharmaceutical sciences and pharmacology. With a strong heritage dating back to 1949, this journal maintains a robust influence, as evidenced by its ranking in the second quartile (Q2) across both Pharmaceutical Science and Pharmacology categories for 2023. The journal is accessible without an open access option, ensuring traditional academic engagement and providing valuable insights for researchers and professionals. It boasts an impressive Scopus ranking, with a percentile positioning of 72nd in Pharmaceutical Science and 67th in Pharmacology. Aimed at fostering innovative research and facilitating the exchange of cutting-edge scientific knowledge, the Journal of Pharmacy and Pharmacology serves as an essential resource for scientists, students, and healthcare professionals committed to enhancing therapeutic outcomes and advancing pharmaceutical innovations.

Nanotechnology Science and Applications, published by DOVE MEDICAL PRESS LTD, is a premier open-access journal dedicated to advancing knowledge in the fields of nanoscience and nanotechnology, particularly focusing on their applications in bioengineering, biomedical engineering, and pharmaceutical sciences. Since its inception in 2008, this journal has provided a platform for the dissemination of high-quality research that is rigorously peer-reviewed, ensuring that only the most impactful findings reach a global audience. With an impressive impact factor reflected in its recent categorization in the Q1 tier for Pharmaceutical Science and Q2 for Bioengineering and Nanoscience, it stands as a critical resource for researchers, practitioners, and students eager to explore the cutting-edge innovations within these rapidly evolving disciplines. The journal's commitment to accessibility and its robust indexing in Scopus—ranked highly in its respective categories—reinforces its importance as a leading forum for the exchange of scientific knowledge and the fostering of collaborative research in nanotechnology applications.

Food Hydrocolloids for Health, published by ELSEVIER, stands at the forefront of research in the fields of food science, gastroenterology, nutrition, and pharmaceutical science. With an ISSN of 2667-0259 and an impressive positioning in the academic community, the journal is ranked Q1 in Food Science and Pharmaceutical Science, alongside Q2 rankings in Gastroenterology and Nutrition and Dietetics as of 2023. This journal serves as a critical platform for disseminating innovative findings related to the health benefits of food hydrocolloids, emphasizing their applications and efficacy in nutrition and medicine. Researchers, professionals, and students can access cutting-edge studies that promote the understanding of health outcomes derived from hydrocolloid-based foods. The journal’s international outreach from the Netherlands facilitates a diverse array of contributions, making it essential for those engaged in advancing knowledge within these dynamic disciplines.

Biomaterials Advances is a premier journal published by Elsevier, dedicated to the rapidly evolving field of biomaterials. Established in the United Kingdom, this open-access journal aims to disseminate high-quality, peer-reviewed research that explores innovative biomaterial designs and their applications in bioengineering and biomedical engineering. With an impressive 2023 impact factor reflected in its Q1 rankings across multiple categories—including Bioengineering, Biomaterials, and Biomedical Engineering—Biomaterials Advances stands out as a critical platform for scholars and practitioners faced with advancing technologies and methodologies in the realm of materials science. Covering a broad range of topics, from biocompatibility to tissue engineering, this journal provides an inclusive forum for researchers seeking to contribute to the field. Its Scopus rankings further affirm its position as a leading resource, with notable standings in Biomedical Engineering (Rank #13), Biomaterials (Rank #8), and Bioengineering (Rank #11), all within the top percentiles. Researchers and students alike are encouraged to contribute and engage with the latest findings and innovations in biomaterials through this valuable publication.